ArticleSurgical endoscopy2026
Prognostic factors and the role of pelvic lymph node dissection in oligometastatic prostate cancer: a multicenter exploratory study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOligometastatic prostate cancer (omPC) represents a specific state with improved outcomes following cytoreductive radical prostatectomy (cRP). Prognostic factors that guide disease progression are yet to be fully elucidated, and the role of pelvic lymph node dissection (LND) in this setting is controversial. This study aimed to evaluate the impact of LND on biochemical progression and castration-resistant prostate cancer (CRPC) in patients with omPC.
methodsA total of 169 omPC patients who underwent cRP with (n = 123) or without LND (n = 46) between January 2015 and February 2024 at multiple centers were retrospectively analyzed. Biochemical progression-free survival (bPFS) and time to CRPC were analyzed using Kaplan-Meier curves and Cox proportional hazards models. Subgroup analysis stratified by nodal status was performed to explore differential treatment effects.
resultsIn the overall cohort, multivariable analysis identified initial PSA > 30 ng/mL as an independent predictor of biochemical progression (HR = 2.53, 95% CI: 1.40-4.58, p = 0.002). For CRPC progression, no variable reached conventional statistical significance in the multivariable model. Stratified analysis revealed that among patients with node-positive disease (N1, n = 40), LND was associated with significantly prolonged bPFS (p = 0.018) and delayed progression to CRPC (p = 0.014). Notably, within the LND cohort (n = 123), N1 patients had significantly higher Gleason scores and T stages, and experienced worse CRPC than N0 patients (p = 0.02).
conclusionIn omPC patients undergoing cRP, high baseline PSA independently predicted biochemical recurrence. Nodal involvement was associated with more aggressive disease features and worse outcomes within the population. An exploratory subgroup analysis suggested that node-positive patients may be associated with improved outcomes after LND; however, this finding was limited by a very small sample size and requires prospective validation.
Indexed as
Identifiers
42426390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.